In order to evaluate the efficiency of target-specific BH3-mimetics in inducing CRC cell death, four human CRC cell lines were treated with WEHI-539 (BCL-XL inhibitor), ABT-199 (BCL-2 inhibitor), and S63845 (MCL-1 inhibitor) in three different concentrations (Fig. 2a). The gene discussed is BCL2L1; the disease is colorectal carcinoma.